Professor Mark James McKeage

MBChB, MMedSc, PhD, FRACP

Biography

Professor Mark McKeage is a physician-scientist with many years experience as research group leader (Cancer Clinical Pharmacology Research Group), practising medical oncologist, clinical trial investigator, graduate student thesis supervisor, and teacher of pharmacology, oncology and clinical medicine. He has over 100 research articles, over 3500 citations and an H-index of 33. His current research seeks to understand mechanisms and develop treatments for platinum drug neurotoxicity and transport-mediated resistance, and to improve lung cancer healthcare via novel genetic testing strategies and targeted therapies.

Currently Professor in the Department of Pharmacology and Clinical Pharmacology, and Co-director of the Auckland Cancer Society Research Centre, he previously he worked at The Institute of Cancer Research and Royal Marsden Hospital (London UK) and the Prince of Wales Hospital, a teaching hospital of the University of New South Wales. 

Visit the Cancer Clinical Pharmacology Group website

Selected publications and creative works (Research Outputs)

  • McKeage, M., Elwood, M., Tin Tin, S., Khwaounjoo, P., Aye, P., Li, A., ... Kingston, N. (2017). EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. Targeted Oncology, 12 (5), 663-675. 10.1007/s11523-017-0515-4
    Other University of Auckland co-authors: Sandar Tin Tin, Mark Elwood
  • Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., ... Rosell, R. (2017). Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 377 (9), 829-838. 10.1056/NEJMoa1704795
  • Han, C. H., Khwaounjoo, P., Hill, A. G., Miskelly, G. M., & McKeage, M. J. (2017). Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation. Scientific reports, 7 (1)10.1038/s41598-017-04383-4
    Other University of Auckland co-authors: Gordon Miskelly, Catherine Han
  • Cui, H., Zhang, A. J., McKeage, M. J., Nott, L. M., Geraghty, D., Guven, N., & Liu, J. J. (2017). Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity. Journal of Inorganic Biochemistry10.1016/j.jinorgbio.2017.04.022
  • Han, C. H., Kilfoyle, D. H., Hill, A. G., Jameson, M. B., & McKeage, M. J. (2016). Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics. Expert Opinion on Drug Metabolism and Toxicology (12), 1479-1490. 10.1080/17425255.2016.1223625
    Other University of Auckland co-authors: Michael Jameson, Catherine Han
  • Yan, F., Liu, J. J., Ip, V., Jamieson, S. M. F., & McKeage, M. J. (2015). Role of platinum DNA damage-induced transcriptional inhibition in chemotherapy-induced neuronal atrophy and peripheral neurotoxicity. Journal of neurochemistry, 135 (6), 1099-1112. 10.1111/jnc.13355
    Other University of Auckland co-authors: Stephen Jamieson
  • Yosaatmadja, Y., Silva, S., Dickson, J. M., Patterson, A. V., Smaill, J. B., Flanagan, J. U., ... Squire, C. J. (2015). Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. Journal of Structural Biology, 192 (3), 539-544. 10.1016/j.jsb.2015.10.018
    URL: http://hdl.handle.net/2292/29811
    Other University of Auckland co-authors: James Dickson, Christopher Squire, Adam Patterson, Jeffrey Smaill, Jack Flanagan, Yuliana Yosaatmadja
  • Myint, K., Li, Y., Paxton, J., & McKeage, M. (2015). Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PloS one, 10 (7)10.1371/journal.pone.0130727